Office Action Dated: October 21, 2003

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1 (Previously Amended) An oligonucleotide comprising a plurality of nucleotides,

wherein:

a first portion of said plurality of nucleotides have B-form conformational geometry and are

joined together in a continuous sequence, at least two of said nucleotides of said first portion being

ribonucleotides; and

a further portion of said plurality of nucleotides are ribonucleotide that have A-form

conformation geometry and are joined together in at least one continuous sequence.

2 (Original). The oligonucleotide of claim 1 wherein each nucleotide of said first portion,

independently, is a 2'-SCH₃ ribonucleotide, a 2'-NH₂ ribonucleotide, a 2'-NH(C₁-C₂ alkyl)

ribonucleotide, a 2'-N(C₁-C₂ alkyl)₂ ribonucleotide, a 2'-CF₃ ribonucleotide, a 2'=CH₂ ribonucleotide,

a 2'=CHF ribonucleotide, a 2'=CF₂ ribonucleotide, a 2'-CH₃ ribonucleotide, a 2'-C₂H₅ ribonucleotide,

a 2'-CH=CH₂ ribonucleotide or a 2'-C≡CH ribonucleotide.

3 (Original). The oligonucleotide of claim 1 wherein each of said nucleotides of said first

portion are joined together in said continuous sequence by phosphate, phosphorothioate,

phosphorodithioate or boranophosphate linkages.

Page 2 of 12

Office Action Dated: October 21, 2003

4 (Previously Amended). The oligonucleotide of claim 1 wherein each nucleotide of said further portion, independently, is a 2'-fluoro nucleotide or a nucleotide having a 2'-substituent having the formula I or II:

$$-O - (CH_2)_{q1} - O - N - Q_1 - Q_1 - Q_2 - Q_2 - Q_3 - Q_2 - Q_1 - Q_2 - Q$$

wherein

E is C_1 - C_{10} alkyl, $N(Q_1)(Q_2)$ or $N=C(Q_1)(Q_2)$;

each Q_1 and Q_2 is, independently, H, C_1 - C_{10} alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group, a linker to a solid support, or Q_1 and Q_2 , together, are joined in a nitrogen protecting group or a ring structure optionally containing at least one additional heteroatom selected from N and O;

 R_3 is OX, SX, or $N(X)_2$;

each X is, independently, H, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C(=NH)N(H)Z, C(=O)N(H)Z or OC(=O)N(H)Z;

Z is H or C_1 - C_8 alkyl;

 L_1 , L_2 and L_3 form a ring system having from about 4 to about 7 carbon atoms or having from about 3 to about 6 carbon atoms and 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur

Office Action Dated: October 21, 2003

and wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic;

Y is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, $N(Q_1)(Q_2)$, $O(Q_1)$, halo, $S(Q_1)$, or CN;

each q₁ is, independently, from 2 to 10;

each q₂ is, independently, 0 or 1;

m is 0, 1 or 2;

p is from 1 to 10; and

 q_3 is from 1 to 10 with the proviso that when p is 0, q_3 is greater than 1.

5 (Original). The oligonucleotide of claim 1 wherein each of said nucleotides of said further portion, independently, is a 2'-F ribonucleotide, a 2'-O-(C_1 - C_6 alkyl) ribonucleotide, or a 2'-O-(C_1 - C_6 substituted alkyl) ribonucleotide wherein the substitution is C_1 - C_6 ether, C_1 - C_6 thioether, amino, amino(C_1 - C_6 alkyl) or amino(C_1 - C_6 alkyl)₂.

6 (Original). The oligonucleotide of claim 1 wherein all of said nucleotides of said further portion are joined together in a continuous sequence by 3'-5' phosphodiester, 2'-5' phosphodiester, phosphorothioate, Sp phosphorothioate, Rp phosphorothioate, phosphorodithioate, 3'-deoxy-3'-

DOCKET NO.: ISIS-4789 PATENT

Application No.: 09/970,971

Office Action Dated: October 21, 2003

amino phosphoroamidate, 3'-methylenephosphonate, methylene(methylimino), dimethylhydrazino,

amide 3, amide 4 or boranophosphate linkages.

7 (Original). The oligonucleotide of claim 1 wherein at least two of said nucleotides of said

further portion are joined together in a continuous sequence that is positioned 3' to said continuous

sequence of said first portion of said plurality of nucleotides.

8 (Original). The oligonucleotide of claim 1 wherein at least two of said nucleotides of said

further portion are joined together in a continuous sequence that is positioned 5' to said continuous

sequence of said first portion.

9 (Original). The oligonucleotide of claim 1 wherein at least two of said nucleotides of said

further portion are joined together in a continuous sequence that is positioned 3' to said continuous

sequence of said first portion and at least two of said further portion are joined together in a

continuous sequence that is positioned 5' to said continuous sequence of said first portion.

10 (Original). The oligonucleotide of claim 1 wherein each nucleotide of said first portion,

independently, is a 2'-SCH₃ ribonucleotide, a 2'-NH₂ ribonucleotide, a 2'-NH(C₁-C₂ alkyl)

ribonucleotide, a 2'-N(C₁-C₂ alkyl)₂ ribonucleotide, a 2'=CH₂ ribonucleotide, a 2'-CH₃ ribonucleotide,

Page 5 of 12

PATENT

DOCKET NO.: ISIS-4789 Application No.: 09/970,971

Office Action Dated: October 21, 2003

a 2'-C₂H₅ ribonucleotide, a 2'-CH=CH₂ ribonucleotide or a 2'-C≡CH ribonucleotide.

11 (Original). The oligonucleotide of claim 1 wherein each nucleotide of said first portion, independently, is a 2'-SCH₃ ribonucleotide, a 2'-NH₂ ribonucleotide a 2'-NH(C₁-C₂ alkyl) ribonucleotide, a 2'-N(C₁-C₂ alkyl)₂ ribonucleotide or a 2'-CH₃ ribonucleotide.

12 (Original). The oligonucleotide of claim 1 wherein each nucleotide of said first portion, independently, is a 2'-SCH₃ ribonucleotide, a 2'-NH₂ ribonucleotide or a 2'-CH₃ ribonucleotide.

13 (Original). The oligonucleotide of claim 1 wherein each nucleotide of said first portion is a 2'-SCH₃ ribonucleotide.

Claims 14-17 (Canceled).

18 (Original). The oligonucleotide of claim 1 wherein each nucleotide of said first portion, independently, is a 2'-SCH₃ ribonucleotide, a 2'-NH₂ ribonucleotide a 2'-NH(C_1 - C_2 alkyl) ribonucleotide, a 2'-N(C_1 - C_2 alkyl)₂ ribonucleotide, a 2'-CH₃ ribonucleotide, a 2'-CH=CH₂ ribonucleotide or a 2'-C=CH ribonucleotide; and

each nucleotide of said further portion, independently, is a 2'-F ribonucleotide, a 2'-O-(C₁-C₆

DOCKET NO.: ISIS-4789 PATENT

Application No.: 09/970,971

Office Action Dated: October 21, 2003

alkyl) ribonucleotide, or a 2'-O-(C₁-C₆ substituted alkyl) ribonucleotide wherein the substitution is

 C_1 - C_6 ether, C_1 - C_6 thioether, amino, amino(C_1 - C_6 alkyl) or amino(C_1 - C_6 alkyl)₂.

Claims 19-20 (Canceled).

21 (Original). The oligonucleotide of claim 1 wherein said further portion comprises at least

two nucleotides joined together in a continuous sequence that is positioned at the 3' terminus end of

said oligonucleotide.

22 (Original). The oligonucleotide of claim 1 wherein said further portion comprises at least

two nucleotides joined together in a continuous sequence that is positioned at the 5' terminus of said

oligonucleotide.

23 (Original). The oligonucleotide of claim 1 wherein said further portion comprises at least

two nucleotides joined together in a continuous sequence that is positions at the 3' terminus of said

oligonucleotide; and

at least two nucleotides joined together in a continuous sequence that is positions at the 5'

terminus of said oligonucleotide.

DOCKET NO.: ISIS-4789

Application No.: 09/970,971

Office Action Dated: October 21, 2003

24 (Original). The oligonucleotide of claim 21 wherein said at least two nucleotides joined

PATENT

together comprise nucleotides joined together by a 2'-5' phosphodiester linkage, a 3'-

methylenephosphonate linkage, a Sp phosphorothioate linkage, a methylene(methylimino) linkage,

a dimethyhydrazino linkage, a 3'-deoxy-3'-amino phosphoroamidate linkage, an amide 3 linkage or

an amide 4 linkage.

25 (Original). The oligonucleotide of claim 24 wherein said two nucleotides are joined

together by a 2'-5' phosphodiester linkage, a 3'-methylenephosphonate linkage, a Sp

phosphorothioate linkage or a methylene(methylimino) linkage.

26 (Original). The oligonucleotide of claim 22 wherein said at least two nucleotides joined

together comprise nucleotides joined together by a 2'-5' phosphodiester linkage, a 3'-

methylenephosphonate linkage, a Sp phosphorothioate linkage, a methylene(methylimino) linkage,

a dimethyhydrazino linkage, a 3'-deoxy-3'-amino phosphoroamidate linkage, an amide 3 linkage or

an amide 4 linkage.

27 (Original). The oligonucleotide of claim 26 wherein said two nucleotides are joined

together by a 2'-5' phosphodiester linkage, a 3'-methylenephosphonate linkage, a Sp

phosphorothioate linkage or a methylene(methylimino) linkage.

Page 8 of 12

DOCKET NO.: ISIS-4789 PATENT

Application No.: 09/970,971

Office Action Dated: October 21, 2003

28 (Original). The oligonucleotide of claim 23 wherein said at least two nucleotides joined

together and positioned at said 3' terminus comprise nucleotides joined together by a 2'-5'

phosphodiester linkage, a 3'-methylenephosphonate linkage, a Sp phosphorothioate linkage, a

methylene(methylimino) linkage, a dimethyhydrazino linkage, a 3'-deoxy-3'-amino

phosphoroamidate linkage, an amide 3 linkage or an amide 4 linkage; and

wherein said at least two nucleotides joined together and positioned at said 5' terminus

comprise nucleotides joined together by a 2'-5' phosphodiester linkage, a 3'-methylenephosphonate

linkage, a Sp phosphorothioate linkage, a methylene(methylimino) linkage, a dimethyhydrazino

linkage, a 3'-deoxy-3'-amino phosphoroamidate linkage, an amide 3 linkage or an amide 4 linkage.

29 (Original). The oligonucleotide of claim 28 wherein said two nucleotides joined together

at said 3' terminus and said two nucleotides joined together at said 5' terminus are, independently,

joined together by 2'-5' phosphodiester linkages, 3'-methylenephosphonate linkages, Sp

phosphorothioate linkages or methylene(methylimino) linkages.

30 (Original). The oligonucleotide of claim 21 wherein at least one of said two nucleotides

joined together is a 2'-alkylamino substituted nucleotide.

31 (Original). The oligonucleotide of claim 22 wherein at least one of said two nucleotides

Page 9 of 12

Office Action Dated: October 21, 2003

joined together is a 2'-alkylamino substituted nucleotide.

32 (Original). The oligonucleotide of claim 23 wherein at least one of said two nucleotides joined together at said 3' terminus is a 2'-alkylamino substituted nucleotide, and

wherein at least one of said two nucleotides joined together at said 5' terminus is a 2'-alkylamino substituted nucleotide.

Claims 33-36 (Canceled).